Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Prevalence of dry eye disease after cataract surgery

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Dry Eye

Session Date/Time: Tuesday 13/09/2016 | 09:30-11:00

Paper Time: 10:10

Venue: Poster Village: Pod 1

First Author: : A.Deka INDIA

Co Author(s): :                  

Abstract Details

Purpose:

To evaluate the prevalence of dry eye diseases following clear corneal phacoemulsification surgery.

Setting:

Bawri Nethralaya, India

Methods:

One hundred eyes from 78 patients were enrolled for this prospective study. Preoperative dry eye evaluation was performed. Preoperative Inflammadry kit (MMP-9 evaluation) negative cases were selected. Values such as tear break-up time (tBUT), Schirmer I test (ST-I), tear meniscus height (TMH), and subjective dry eye symptoms (Sx) are recorded and evaluated the postoperative changes in these values. The correlations between corneal incision location, microscopic light exposure time and phacoemulsification energy were evaluated.

Results:

There were aggravations in Sx in 30% at 1 month postoperatively and in tBUT (p < 0.05) in 48% at 3 days, 10 days and 1 month postoperatively. Inflammadry kit test was negative postoperatively. All dry eye test values were worse transiently after cataract surgery and started improving without treatment after 1 month. With regard to incision location, there was no difference (p > 0.05).

Conclusions:

Cataract surgery may lead to mild to moderate dry eye. However, in most of cases, it is transiently and improves with out dry eye therapy. Through incision site and phacoemulsification power significantly don’t alter dry eye test values, however prolong microscopic light exposure times can have an adverse effect on dry eye test values.

Financial Disclosure:

NONE

Back to previous